If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
677.00    95.00 (16.32%)
Bid:
682.00
Ask:
685.00
Spread: 3.00 (0.44%)
Market Cap: £589.84m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Q1 Trading Update

6 Feb 2026 07:00

RNS Number : 9609R
Victrex PLC
06 February 2026
 
 

6 February 2026

Victrex plc - AGM & Q1 trading update

'YTD volumes in line with prior year: FY guidance maintained'

Victrex plc is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Today's trading update covers the first quarter (Q1) of FY 2026, from 1 October 2025 to 31 December 2025.

 

Q1 performance summary

 

o Q1 (3 months ended 31 December 2025) volumes reduced by 4%, reflecting growth in Energy & Industrial offset by a more subdued performance in Transport, Value Added Resellers (VARs) and Medical

o Average selling price (ASP) was broadly in line with the prior year

 

Quarter ended 31 December 2025 (Q1)

Q1 2026

 

Q1 2025

% change

Sales volume (tonnes)

858

898

-4%

Revenue (£m)

62.4

66.6

-6%

ASP (£/kg)

73

74

-2%

 

Year to date ('YTD') performance

 

· YTD (4 months ended 31 January 2026) volumes in line with prior year, with January recovering some of the shortfall from a weaker December

· YTD revenues slightly lower than prior year, primarily reflecting sales mix

· As previously communicated, FY 2026 performance is expected to be weighted to the second half

· Performance in H1 2026 is expected to be weaker than H1 2025, reflecting the weaker end to Q1 and the currency headwind being weighted to the first half

 

Divisional and end-market performance

In our Sustainable Solutions business, Energy & Industrial continues to perform well as activity levels remain healthy within this end market. Whilst VARs saw a slower start in Q1, momentum improved at the start of Q2. YTD volumes in VARs are now ahead of the prior year.

Medical revenues remain slightly below the prior year on a YTD basis, with January seeing the normal seasonal improvement over Q1.

 

Financial position

Net debt at 31 December was £21.1m, with cash of £28m. This is prior to payment of the FY 2025 final dividend (46.14p/share), totalling approximately £40m, later this month. Total dividends per share for FY 2025 were 59.56p.

 

Profit Improvement Plan

Actions are progressing at pace to deliver our Profit Improvement Plan which is focused on three pillars: Portfolio simplification, operating efficiency and overhead costs. We are targeting annualised cost savings of at least £10m to be realised in FY 2027, with some initial benefits during the latter part of H2 2026. We will provide an update on progress at our interim results.

 

Outlook: full-year guidance unchanged

Dr James Routh, Chief Executive Officer of Victrex, said:

 

"The start of FY 2026 reflected usual Q1 seasonality, alongside a subdued performance across some end-markets. On a year to date basis, our second quarter started solidly, with YTD volumes now in line with the prior year. Whilst we continue to be mindful of wider macroeconomic conditions, our full year guidance remains unchanged. As previously communicated, performance will be weighted to the second half. The first half is expected to be weaker than the prior year.

 

"At this early stage of my tenure, I have been impressed with our innovation know-how, our breadth of growth opportunities and the passion of our talented people to rapidly adapt and improve our financial performance. FY 2026 will be a transitional year, with our Profit Improvement Plan helping us become a more efficient, growth focused and performance oriented company. By further differentiating our business and creating a more agile and customer-focused organisation, we will unlock Victrex's potential and better position the company for sustainable growth over the medium to longer term."

 

Annual General Meeting

Victrex's Annual General Meeting will be held today, starting at 11.00am GMT and taking place at JP Morgan, 1 John Carpenter Street, London EC4Y 0JP, United Kingdom.

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 59583

Ian Melling, Chief Financial Officer

+44 (0) 1253 897700

Dr James Routh, Chief Executive Officer

+44 (0) 1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aircraft and cars to energy operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

 

Forward looking statements:

This announcement has been prepared solely to provide additional information to the shareholders of Victrex plc, to meet the requirements of the FCA's Disclosure and Transparency Rules. It should not be relied on by any other party, for any other purposes. Forward-looking statements have been made by the directors in good faith, using information available up until the date on which they approved this statement. Forward-looking statements should be regarded with caution, because of the inherent uncertainties in economic trends and business risks.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUGUPUPQGRA
Date   Source Headline
8th Jul 20207:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202011:30 amRNSTotal Voting Rights
17th Jun 202011:44 amRNSDirector/PDMR Shareholding
15th Jun 20204:24 pmRNSHolding(s) in Company
4th Jun 20208:54 amRNSAdditional Listing
3rd Jun 20202:52 pmRNSHolding(s) in Company
1st Jun 20202:33 pmRNSBlock listing Interim Review
29th May 202011:58 amRNSTotal Voting Rights
21st May 20203:14 pmRNSHolding(s) in Company
19th May 202010:31 amRNSDirector/PDMR Shareholding
18th May 202010:19 amRNSDirector Declaration
11th May 20207:00 amRNSVictrex plc Interim Results
5th May 20204:13 pmRNSDisclosure of Rights Attached to Equity Shares
5th May 20209:00 amRNSDirector Declaration
30th Apr 202011:39 amRNSTotal Voting Rights
17th Apr 202012:04 pmRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSMarket Update
3rd Apr 20207:00 amRNSDirector Declaration
31st Mar 20209:22 amRNSTotal Voting Rights
24th Mar 20202:00 pmRNSDirectorate Change
17th Mar 20203:32 pmRNSHolding(s) in Company
17th Mar 20202:52 pmRNSDirector/PDMR Shareholding
16th Mar 202010:05 amRNSHolding(s) in Company
12th Mar 202012:47 pmRNSDirector/PDMR Shareholding
3rd Mar 20209:49 amRNSDirector/PDMR Shareholding
28th Feb 202011:56 amRNSTotal Voting Rights
20th Feb 20204:50 pmRNSDirector/PDMR Shareholding
13th Feb 20201:59 pmRNSDirector/PDMR Shareholding
6th Feb 20202:34 pmRNSDirector/PDMR Shareholding
6th Feb 20201:20 pmRNSResult of AGM
6th Feb 202010:54 amRNSDirector/PDMR Shareholding
6th Feb 20207:00 amRNSAGM and Q1 Interim Management Statement
5th Feb 20204:22 pmRNSHolding(s) in Company
4th Feb 20203:42 pmRNSHolding(s) in Company
31st Jan 202010:39 amRNSTotal Voting Rights
20th Jan 202010:04 amRNSDirector/PDMR Shareholding
17th Jan 202010:38 amRNSDirector/PDMR Shareholding
13th Jan 20204:06 pmRNSHolding(s) in Company
13th Jan 20208:46 amRNSJoint Venture
3rd Jan 202012:00 pmRNSAnnual Financial Report
31st Dec 20199:00 amRNSTotal Voting Rights
23rd Dec 20191:44 pmRNSHolding(s) in Company
17th Dec 20192:20 pmRNSDirector/PDMR Shareholding
12th Dec 201910:04 amRNSDirector/PDMR Shareholding
5th Dec 20197:00 amRNSPreliminary Results 2019
2nd Dec 20191:52 pmRNSBlock listing Interim Review
29th Nov 201911:38 amRNSTotal Voting Rights
19th Nov 201911:02 amRNSDirector/PDMR Shareholding
12th Nov 201912:00 pmRNSDirectorate Change
31st Oct 201911:36 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.